- Home
- ATGE vs XENE Comparison
ATGE vs XENE Comparison
Compare ATGE & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATGE
- XENE
- Stock Information
- Founded
- ATGE 1987
- XENE 1996
- Country
- ATGE United States
- XENE Canada
- Employees
- ATGE N/A
- XENE N/A
- Industry
- ATGE Other Consumer Services
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- ATGE Consumer Discretionary
- XENE Health Care
- Exchange
- ATGE Nasdaq
- XENE Nasdaq
- Market Cap
- ATGE 2.7B
- XENE 3.3B
- IPO Year
- ATGE 1991
- XENE 2014
- Fundamental
- Price
- ATGE $90.03
- XENE $38.74
- Analyst Decision
- ATGE Buy
- XENE Strong Buy
- Analyst Count
- ATGE 3
- XENE 8
- Target Price
- ATGE $85.00
- XENE $56.00
- AVG Volume (30 Days)
- ATGE 398.5K
- XENE 384.9K
- Earning Date
- ATGE 01-28-2025
- XENE 11-12-2024
- Dividend Yield
- ATGE N/A
- XENE N/A
- EPS Growth
- ATGE 88.45
- XENE N/A
- EPS
- ATGE 4.36
- XENE N/A
- Revenue
- ATGE $1,633,207,000.00
- XENE N/A
- Revenue This Year
- ATGE $10.81
- XENE N/A
- Revenue Next Year
- ATGE $6.15
- XENE $1,599.99
- P/E Ratio
- ATGE $21.11
- XENE N/A
- Revenue Growth
- ATGE 11.45
- XENE N/A
- 52 Week Low
- ATGE $43.78
- XENE $35.53
- 52 Week High
- ATGE $92.93
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- ATGE 59.07
- XENE 43.92
- Support Level
- ATGE $84.79
- XENE $37.61
- Resistance Level
- ATGE $91.99
- XENE $39.49
- Average True Range (ATR)
- ATGE 2.69
- XENE 1.56
- MACD
- ATGE -0.05
- XENE -0.20
- Stochastic Oscillator
- ATGE 90.89
- XENE 29.86
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.